Dreisbach A, Lertora J
Expert Opin Drug Metab Toxicol. 2008; 4(8):1065-74.
PMID: 18680441
PMC: 2745294.
DOI: 10.1517/17425255.4.8.1065.
Rocha G, Michea L, Peters E, Kirby M, Xu Y, Ferguson D
Proc Natl Acad Sci U S A. 2001; 98(9):5317-22.
PMID: 11320259
PMC: 33207.
DOI: 10.1073/pnas.091057698.
Russo H, Bressolle F
Clin Pharmacokinet. 1998; 35(2):95-134.
PMID: 9739479
DOI: 10.2165/00003088-199835020-00002.
Russo H, Bres J, Duboin M, Roquefeuil B
Eur J Clin Pharmacol. 1995; 49(1-2):127-37.
PMID: 8751034
DOI: 10.1007/BF00192371.
Snoeck E, Van Peer A, Sack M, Horton M, Mannens G, Woestenborghs R
Psychopharmacology (Berl). 1995; 122(3):223-9.
PMID: 8748391
DOI: 10.1007/BF02246543.
Plasma protein binding of azapropazone in patients with kidney and liver disease.
Jahnchen E, Blanck K, Breuing K, Gilfrich H, Meinertz T, Trenk D
Br J Clin Pharmacol. 1981; 11(4):361-7.
PMID: 7259929
PMC: 1401678.
DOI: 10.1111/j.1365-2125.1981.tb01133.x.
Thiopentone-induced changes in the contraction pattern of vascular smooth muscle: the influence of albumin.
Andreasen F, Christensen J
Br J Pharmacol. 1984; 82(3):643-50.
PMID: 6743917
PMC: 1986994.
DOI: 10.1111/j.1476-5381.1984.tb10802.x.
Alteration of drug-protein binding in renal disease.
Reidenberg M, Drayer D
Clin Pharmacokinet. 1984; 9 Suppl 1:18-26.
PMID: 6705423
DOI: 10.2165/00003088-198400091-00003.
Level of consciousness after cadaveric kidney transplant under halothane anaesthesia.
Casthely P, Villanueva R
Can Anaesth Soc J. 1983; 30(6):587-92.
PMID: 6357401
DOI: 10.1007/BF03015227.
Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.
Verbeeck R, Blackburn J, Loewen G
Clin Pharmacokinet. 1983; 8(4):297-331.
PMID: 6352138
DOI: 10.2165/00003088-198308040-00003.
Kinetics of salicylate elimination by anephric patients.
Lowenthal D, Briggs W, Levy G
J Clin Invest. 1974; 54(5):1221-6.
PMID: 4424666
PMC: 301669.
DOI: 10.1172/JCI107865.
Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease.
Laznicek M, Senius K
Eur J Clin Pharmacol. 1986; 30(5):591-6.
PMID: 3758148
DOI: 10.1007/BF00542420.
Free drug concentration monitoring in clinical practice. Rationale and current status.
Svensson C, Woodruff M, BAXTER J, Lalka D
Clin Pharmacokinet. 1986; 11(6):450-69.
PMID: 3542337
DOI: 10.2165/00003088-198611060-00003.
Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.
Lin J, Cocchetto D, DUGGAN D
Clin Pharmacokinet. 1987; 12(6):402-32.
PMID: 3301150
DOI: 10.2165/00003088-198712060-00002.
Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition.
Gaspari F, Vigano G, Orisio S, Bonati M, Livio M, Remuzzi G
J Clin Invest. 1987; 79(6):1788-97.
PMID: 3108321
PMC: 424522.
DOI: 10.1172/JCI113020.
Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).
Zini R, Riant P, Barre J, Tillement J
Clin Pharmacokinet. 1990; 19(3):218-29.
PMID: 2203581
DOI: 10.2165/00003088-199019030-00005.
The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment.
Viani A, Rizzo G, Carrai M, Pacifici G
Br J Clin Pharmacol. 1992; 33(3):299-304.
PMID: 1576051
PMC: 1381279.
DOI: 10.1111/j.1365-2125.1992.tb04039.x.
Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences.
Pacifici G, Viani A
Clin Pharmacokinet. 1992; 23(6):449-68.
PMID: 1458763
DOI: 10.2165/00003088-199223060-00005.
Plasma protein binding of phenylbutazone during recovery from acute renal failure.
Mussche M, Belpaire F, Bogaert M
Eur J Clin Pharmacol. 1975; 9(1):69-71.
PMID: 1233255
DOI: 10.1007/BF00613431.
Decreased drug binding in serum from patients with chronic hepatic disease.
Wallace S, Brodie M
Eur J Clin Pharmacol. 1976; 09(5-6):429-32.
PMID: 971706
DOI: 10.1007/BF00606560.
